Alkem Foundation, IIT Bombay to Set Up Advanced Research Centre
ECONOMY & POLICY

Alkem Foundation, IIT Bombay to Set Up Advanced Research Centre

Mumbai, November 3, 2025 — Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories, has announced a strategic collaboration with the Indian Institute of Technology Bombay (IIT Bombay) to establish a first-of-its-kind research centre in India dedicated to immuno-therapeutics and regenerative medicines.

Under this partnership, Alkem Foundation will fund the creation of the Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines within the IIT Bombay campus. The foundation will contribute around 20–25 per cent of its cumulative CSR obligations over seven years towards this project.

The initiative marks India’s first industry–academia collaboration, initiated through the CSR route, to promote advanced research in these complex therapeutic areas. It will combine Alkem’s experience in developing pharmaceutical solutions with IIT Bombay’s expertise in biomedical engineering, biosciences, and translational research to create an innovation-driven ecosystem.

The centre aims to build a holistic platform for research, innovation, and skill development in high-precision and underserved therapy areas, bridging gaps in infrastructure, talent, and translational capability. It will also align with IIT Bombay’s multidisciplinary healthcare approach that integrates biology, engineering, and data science to advance human health.

Future research will explore frontier domains such as gene editing, biomaterials, and delivery technologies for immuno-therapeutics and regenerative medicine. The centre will serve as a hub for clinician-scientists and biotech entrepreneurs, supported by IIT Bombay faculty, Alkem mentors, and global experts from leading universities.

Madhurima Singh, Executive Director and Chairperson, CSR and Sustainability Committee, Alkem, said, “We believe in going beyond business to support R&D in areas of significant medical need. Our partnership with IIT Bombay reflects a shared commitment to fostering innovation and developing advanced, affordable treatments that can enhance both lifespan and quality of life.”

Prof. Shireesh B. Kedare, Director, IIT Bombay, added, “This collaboration will accelerate translation of cutting-edge research into real-world healthcare impact, helping India achieve self-reliance in biomedical innovation.”

Mumbai, November 3, 2025 — Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories, has announced a strategic collaboration with the Indian Institute of Technology Bombay (IIT Bombay) to establish a first-of-its-kind research centre in India dedicated to immuno-therapeutics and regenerative medicines. Under this partnership, Alkem Foundation will fund the creation of the Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines within the IIT Bombay campus. The foundation will contribute around 20–25 per cent of its cumulative CSR obligations over seven years towards this project. The initiative marks India’s first industry–academia collaboration, initiated through the CSR route, to promote advanced research in these complex therapeutic areas. It will combine Alkem’s experience in developing pharmaceutical solutions with IIT Bombay’s expertise in biomedical engineering, biosciences, and translational research to create an innovation-driven ecosystem. The centre aims to build a holistic platform for research, innovation, and skill development in high-precision and underserved therapy areas, bridging gaps in infrastructure, talent, and translational capability. It will also align with IIT Bombay’s multidisciplinary healthcare approach that integrates biology, engineering, and data science to advance human health. Future research will explore frontier domains such as gene editing, biomaterials, and delivery technologies for immuno-therapeutics and regenerative medicine. The centre will serve as a hub for clinician-scientists and biotech entrepreneurs, supported by IIT Bombay faculty, Alkem mentors, and global experts from leading universities. Madhurima Singh, Executive Director and Chairperson, CSR and Sustainability Committee, Alkem, said, “We believe in going beyond business to support R&D in areas of significant medical need. Our partnership with IIT Bombay reflects a shared commitment to fostering innovation and developing advanced, affordable treatments that can enhance both lifespan and quality of life.” Prof. Shireesh B. Kedare, Director, IIT Bombay, added, “This collaboration will accelerate translation of cutting-edge research into real-world healthcare impact, helping India achieve self-reliance in biomedical innovation.”

Related Stories

Gold Stories

Next Story
Products

Koemmerling opens Navi Mumbai experience centre

Koemmerling, a brand of the profine Group, has expanded its presence in the Mumbai metropolitan region with the opening of a new experience centre in Navi Mumbai and launched its Allure S46 minimal sliding door system for the Indian market.Located in CBD Belapur, the facility was inaugurated by Peter Mrosik, Owner and CEO, profine Group, along with Farid Khan, Chairman and Managing Director, profine India, and Kamal Bajaj, CEO, profine India.The company said the new centre will showcase its portfolio of uPVC and aluminium window and door systems to architects, developers and homeowners.The ina..

Next Story
Products

India's waterproofing market nears Rs 150 bn milestone

India's waterproofing industry is approaching a market size of Rs 150 billion and is expected to surpass the $2 billion milestone, according to speakers at the 2nd India International Waterproofers Conference & Expo 2026 organised by the Waterproofers Association of India (WAI) in New Delhi.The two-day event brought together more than 20 speakers, 55 international delegates and 53 exhibition booths, with discussions focusing on climate-resilient construction, advanced waterproofing technologies and international collaboration.Inaugurating the event, Durga Shanker Mishra, former Secretary, ..

Next Story
Real Estate

Dilip Buildcon Q1 FY27 Revenue at Rs 23.78 billion

Dilip Buildcon Limited reported consolidated revenue from operations of Rs 2,378 crore in Q1 FY27, along with EBITDA of Rs 429 crore and profit after tax of Rs 128 crore.Consolidated EBITDA margin stood at 18.1%, improving from 17.1% in Q4 FY26. On a standalone basis, revenue from operations was Rs 1,930 crore, EBITDA stood at Rs 199 crore and PAT was Rs 39 crore, with an EBITDA margin of 10.3%.The company’s order book stood at Rs 27,691 crore as of 30 June 2026, compared with Rs 28,830 crore as of 31 March 2026. Roads and highways accounted for 17.1% of the order book, irrigation and water ..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement